Antibodies against human angiopoietin 2
The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6. The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6.
1. A method of inhibiting tumor growth in a patient comprising administering, to a patient in need thereof, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises the CDR3 region of SEQ ID NO: 1, the CDR2 region of SEQ ID NO: 2 and the CDR1 region of SEQ ID NO: 3; and (B) a light chain variable domain which comprises the CDR3 region of SEQ ID NO: 4, the CDR2 region of SEQ ID NO: 5 and the CDR1 region of SEQ ID NO: 6.
2. A method according to claim 1 wherein said tumor is colorectal, breast, or lung.
3. A method according to claim 1 wherein said heavy chain variable domain has the sequence of SEQ ID NO: 7 and said light chain variable domain has the sequence of SEQ ID NO: 8.
4. A method for inhibiting metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises the CDR3 region of SEQ ID NO: 1, the CDR2 region of SEQ ID NO: 2 and the CDR1 region of SEQ ID NO: 3; and (B) a light chain variable domain which comprises the CDR3 region of SEQ ID NO: 4, the CDR2 region of SEQ ID NO: 5 and the CDR1 region of SEQ ID NO: 6.
5. A method according to claim 4 wherein said heavy chain variable domain has the sequence of SEQ ID NO: 7 and said light chain variable domain has the sequence of SEQ ID NO: 8.